Compare ASTC & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASTC | INAB |
|---|---|---|
| Founded | 1984 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5M | 11.8M |
| IPO Year | 2020 | 2020 |
| Metric | ASTC | INAB |
|---|---|---|
| Price | $4.82 | $0.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 25.8K | ★ 37.2K |
| Earning Date | 11-12-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2600.00 | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $1,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $21.40 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.92 | $0.87 |
| 52 Week High | $68.85 | $2.73 |
| Indicator | ASTC | INAB |
|---|---|---|
| Relative Strength Index (RSI) | 32.20 | 34.87 |
| Support Level | $4.63 | $0.92 |
| Resistance Level | $7.76 | $1.50 |
| Average True Range (ATR) | 0.41 | 0.09 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 19.55 | 14.08 |
Astrotech Corp is a science and technology company. It creates, operates and scales businesses through its subsidiaries and technology platforms, including space-related technology, instrumentation, mass spectrometry, gas chromatography, process-control and environmental analysis technologies. It is evaluating opportunities to identify, develop and commercialize technologies with potential applications in space, defense, industrial, environmental, quantum computing, AI, semiconductor materials, lunar infrastructure and related markets. Its products include Tracer 1000 ETD, tracer 1000 NTD, Labrador HHGC, Fenceline GC, AgLab 1000-D2, among others. It operates in single segment.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.